While deletions of IKZF1 are a well-established marker of adverse outcomes in ALL portraying substantially higher relapse rates and shortened survival [22, 30–35], evidence on the impact of IKZF1 alterations in AML is sparse. This evidence concerns the gene IKZF1 and acute myeloid leukemia.